Fantastic RNS14 Jun 2018 12:34
Well done VAL! Clinical study report for VAL 401, (fantastic drug for lung cancer, which alleviates the distress of painful side effects from more invasive treatments, extending quality of life and life expectancy), due in July 2018 alongside major trial approval which is expected. The market will really move when we get definite news. This is the last chance to get some cheap shares. All the moaning is from impatient investors who bought on a spike into a tiny bio tech with massive potential but they expect the company to achieve it's potential the day after they invested!